⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 20, 2024World Journal of Surgical OncologyOpen Access

Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis

Lin-Yu Xia Xuchen Cao Yue Yu

View Full Paper

Ask AI

Bookmark

Share

Abstract

The survival outcomes in HER2-low versus HER2-zero breast cancer (BC) after neoadjuvant chemotherapy (NACT) remain unclear. The meta-analysis was conducted to summarize current evidence about the survival outcomes in HER2-low versus HER2-zero BC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xia et al. (2024) studied this question.

synapsesocial.com/papers/68e6e3f4b6db64358765ff43 https://doi.org/10.1186/s12957-024-03382-w

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy2024 · 23 citations
2The impact of HER2 low positivity in hormone receptor-positive, HER2-negative breast cancer treated with neoadjuvant chemotherapyRetrospective Study · 2026 · 1 citations
3Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancerPrognostic Study · 2023 · 28 citations
4HER2-Low Versus HER2-Zero Breast Cancer in the Neoadjuvant Setting: Pathological Complete Response and Exploratory Survival Outcomes in a Single-Center CohortCohort Study · 2026
5Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer2024 · 22 citations

More related papers

Evolution and prognostic significance of HER-2 changes from primary to residual disease in patients with HER-2–negative breast cancer receiving neoadjuvant chemotherapy.2024
Abstract PO5-17-09: Event-free survival in HER2-low vs HER2-zero breast cancer patients submitted to neoadjuvant chemotherapy2024
HER2-low as a unique subgroup in breast cancer: insights from neoadjuvant chemotherapy response and survival analysis2026

More from World Journal of Surgical Oncology

Health-related quality of life as a mediator of the association between sleep quality and depressive symptoms in patients with gastric cancerMon,
Long-term survival comparison of endoscopic resection versus surgical resection for early gastric cancer: a propensity score-matched analysis based on the SEER databaseFri,